NCT05879159 Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection
| NCT ID | NCT05879159 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Liver |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2023-10-05 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2023-10-05 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To learn if an accelerated recovery program can shorten the length of hospital stay in patients having minimally invasive liver surgery.
Eligibility Criteria
Inclusion Criteria: * Tumor amenable to MIS Kawaguchi-Gayet grade I hepatectomy (see figure 1 below) * No evidence of cirrhosis (based on imaging, evidence of portal hypertension, clinical features, or laboratory results) * No significant cardiopulmonary disease that would prevent patients from undergoing MIS resection * Ability to stay within 50 miles of medical center for immediate postop period * Age of 18 years or above - because no adverse event data are currently available on enhanced recovery and early discharge after hepatic resection for patients \<18 years of age, children are excluded from this study * Ability to understand and the willingness to sign a written informed consent document * Non-English-speaking patients are eligible for participation Exclusion Criteria: Patients who will be excluded include those with: * Tumors NOT amenable to MIS Kawaguchi-Gayet grade I hepatectomy * Tumors not amenable to MIS or Robotic-assisted surgical resection * Evidence of Cirrhosis on imaging, clinically, or lab testing * Inability to stay within 50 miles of the Cancer Center in the immediate post-operative period * Age below 18 years * Inability to consent for trial/protocol * Patients who are pregnant
Contact & Investigator
Hop Tran Cao, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT05879159 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Liver. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05879159 currently recruiting?
Yes, NCT05879159 is actively recruiting participants. Contact the research team at hstran@mdanderson.org for enrollment information.
Where is the NCT05879159 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT05879159 clinical trial?
NCT05879159 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Hop Tran Cao, MD at M.D. Anderson Cancer Center. The trial plans to enroll 36 participants.